PMID- 36651471
OWN - NLM
STAT- MEDLINE
DCOM- 20230329
LR  - 20230329
IS  - 1744-8301 (Electronic)
IS  - 1479-6694 (Linking)
VI  - 19
IP  - 1
DP  - 2023 Jan
TI  - Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell 
      lymphoma.
PG  - 19-28
LID - 10.2217/fon-2022-0774 [doi]
AB  - Lisocabtagene maraleucel (liso-cel) is one of the three US FDA-approved chimeric 
      antigen receptor T-cell therapies for the treatment of relapsed/refractory (R/R) 
      large B-cell lymphoma (LBCL). TRANSCEND is the landmark trial that led to the 
      approval of liso-cel in the third-line setting for R/R diffuse LBCL, primary 
      mediastinal B-cell lymphoma, follicular lymphoma grade 3B and transformed 
      lymphoma. The TRANSFORM and PILOT studies evaluated the use of liso-cel in the 
      second-line treatment of R/R LBCL. This review details the structure and 
      manufacturing process of liso-cel that make it distinct from other approved 
      chimeric antigen receptor constructs, outlines results from landmark trials of 
      liso-cel in LBCL and discusses liso-cel toxicity.
FAU - St-Pierre, Frederique
AU  - St-Pierre F
AUID- ORCID: 0000-0002-8495-8579
AD  - Department of Medicine, Division of Hematology/Oncology & the Robert H. Lurie 
      Comprehensive Cancer Center of Northwestern University, Chicago, IL 60208, USA.
FAU - Gordon, Leo I
AU  - Gordon LI
AD  - Department of Medicine, Division of Hematology/Oncology & the Robert H. Lurie 
      Comprehensive Cancer Center of Northwestern University, Chicago, IL 60208, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230118
PL  - England
TA  - Future Oncol
JT  - Future oncology (London, England)
JID - 101256629
RN  - 0 (Receptors, Chimeric Antigen)
RN  - 0 (Antigens, CD19)
SB  - IM
MH  - Humans
MH  - *Receptors, Chimeric Antigen
MH  - *Lymphoma, Large B-Cell, Diffuse/drug therapy
MH  - *Lymphoma, Non-Hodgkin
MH  - B-Lymphocytes
MH  - *Lymphoma, Follicular
MH  - Immunotherapy, Adoptive/adverse effects
MH  - Antigens, CD19
OAB - Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment for large 
      B-cell lymphoma (LBCL). CAR T involves modifying a patient's immune cells (T 
      cells, specifically), so that they can attack cancer cells and destroy them. 
      Lisocabtagene maraleucel (liso-cel) is a type of CAR T-cell therapy that has been 
      approved to treat patients with LBCL who have already received at least one line 
      of treatment for their lymphoma. This article outlines the structure and 
      manufacturing process of liso-cel and discusses how it differs from other 
      approved CAR T-cell therapies. It also summarizes the clinical data for liso-cel 
      in the treatment of LBCL, as well as its safety and expected side effects.
OABL- eng
OTO - NOTNLM
OT  - CAR T-cell therapy
OT  - large B-cell lymphoma
OT  - lisocabtagene maraleucel
EDAT- 2023/01/19 06:00
MHDA- 2023/03/29 06:05
CRDT- 2023/01/18 06:42
PHST- 2023/03/29 06:05 [medline]
PHST- 2023/01/19 06:00 [pubmed]
PHST- 2023/01/18 06:42 [entrez]
AID - 10.2217/fon-2022-0774 [doi]
PST - ppublish
SO  - Future Oncol. 2023 Jan;19(1):19-28. doi: 10.2217/fon-2022-0774. Epub 2023 Jan 18.